Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer

ABSTRACT Background Recent evidence indicates that a dysregulated host metabolism influences treatment outcomes in patients with breast cancer. We investigated the association of computed tomography (CT)‐derived body composition indices with therapeutic responses in patients with hormone receptor‐po...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hyunwook Kim, Seungjin Baek, Sookyeong Han, Gun Min Kim, Joohyuk Sohn, Yumie Rhee, Namki Hong, Min Hwan Kim
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Series:	Journal of Cachexia, Sarcopenia and Muscle
Subjects:	breast cancer CDK4/6 inhibitors CT‐derived body composition low skeletal muscle radiodensity muscle density
Online Access:	https://doi.org/10.1002/jcsm.13666
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association of Muscle Radiodensity and Muscle Mass With Thoracic Aortic Calcification Progression in Dialysis Patients
by: Xiao‐xu Wang, et al.
Published: (2025-04-01)

Inverse Association of Longitudinal Variations in Fat Tissue Radiodensity and Area
by: Giulia Besutti, et al.
Published: (2025-06-01)

Lesson from a metastatic male breast cancer case: CDK4/6 plus aromatase inhibitors could not exceed tamoxifen
by: Tala Najdi, et al.
Published: (2025-05-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

In silico identification of novel CDK4 inhibitors for retinoblastoma
by: Mukesh kumar, et al.
Published: (2024-12-01)

Age- and sex-adjusted CT-based reference values for temporal muscle thickness, cross-sectional area and radiodensity
by: Emilia K. Pesonen, et al.
Published: (2025-01-01)

The efficacy of using the allogeneic osteoplastic material in skull trepanation
by: A. A. Ofitserov, et al.
Published: (2024-03-01)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
by: Alireza Azimi, et al.
Published: (2018-03-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

CDK4/6 inhibitor-associated vortex keratopathy: a case report
by: Lian Shu, et al.
Published: (2025-04-01)

CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells
by: Miaomiao Chen, et al.
Published: (2025-07-01)

Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
by: Dokyeong Kim, et al.
Published: (2025-02-01)

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01)

Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors
by: Jinming Yang, et al.
Published: (2025-08-01)

Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer
by: Laura-Florentina Rebegea, et al.
Published: (2025-05-01)

CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer
by: Wen-Chi Yang, et al.
Published: (2025-08-01)

The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i
by: Mohamed Khalifa, et al.
Published: (2025-04-01)

Identification and evaluation of pyrimidine based CDK6 inhibitors against glioblastoma using integrated computational approaches
by: Hina Manzoor, et al.
Published: (2025-07-01)

Age-related changes in skeletal muscle mitochondria: the role of exercise
by: Dae Yun Seo, et al.
Published: (2016-09-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment
by: Tong Gao, et al.
Published: (2025-05-01)

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
by: Efthymia Skafida, et al.
Published: (2023-01-01)

Transcriptional regulation of autophagy in skeletal muscle stem cells
by: Priya D. Gopal Krishnan, et al.
Published: (2025-02-01)

An in silico and in vitro approach for understanding CDK2 expression pattern and prognostic implications in breast cancer
by: Fatima Manhas, et al.
Published: (2025-05-01)

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
by: Seda Kahraman, et al.
Published: (2024-12-01)

Body composition as a potential imaging biomarker for predicting the progression risk of chronic kidney disease
by: Zhouyan Liao, et al.
Published: (2024-10-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat
by: Stefan Senekowitsch, et al.
Published: (2025-03-01)

Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
by: Binliang Liu, et al.
Published: (2024-12-01)

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01)

Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study
by: Yan‐Ling Wen, et al.
Published: (2025-06-01)

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
by: Wensheng Liu, et al.
Published: (2025-05-01)

Monitoring concentration and lipid signature of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment
by: Mathilde Richard, et al.
Published: (2024-12-01)

Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis
by: Jinbeom Heo, et al.
Published: (2019-11-01)

Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity
by: Asmaa A. Mandour, et al.
Published: (2022-12-01)

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
by: İrem Öner, et al.
Published: (2025-02-01)